Company profile for Allena Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD,...
Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. Allena’s proprietary technological approach enables the design, formulation and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
One Newton Executive Park Suite 202 Newton, MA 02462
Telephone
Telephone
617-467-4577
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2022/07/12/2478539/0/en/Allena-Pharmaceuticals-Announces-New-Meeting-Date-and-New-Record-Date-for-Special-Meeting-to-Approve-Reverse-Stock-Split.html

GLOBENEWSWIRE
12 Jul 2022

https://www.globenewswire.com/news-release/2022/07/05/2473843/0/en/Allena-Pharmaceuticals-Announces-Rescheduling-of-Special-Meeting-to-Approve-Reverse-Stock-Split.html

GLOBENEWSWIRE
05 Jul 2022

https://www.globenewswire.com/news-release/2022/05/04/2435608/0/en/Allena-Pharmaceuticals-Announces-2-8-Million-Registered-Direct-Offering.html

GLOBENEWSWIRE
04 May 2022

https://www.globenewswire.com/news-release/2021/11/03/2326300/0/en/Allena-Pharmaceuticals-Receives-Fast-Track-Designation-from-FDA-for-the-Development-of-ALLN-346-for-Chronic-Treatment-of-Hyperuricemia-in-Patients-With-Gout-and-Advanced-Chronic-Ki.html

GLOBENEWSWIRE
03 Nov 2021

https://www.globenewswire.com/news-release/2021/09/29/2305328/0/en/Allena-Pharmaceuticals-Commences-Dosing-of-Gout-Patients-in-Second-Phase-2a-Trial-of-ALLN-346.html

GLOBENEWSWIRE
29 Sep 2021

https://www.globenewswire.com/news-release/2021/07/14/2262419/0/en/Allena-Pharmaceuticals-Announces-28-Million-Registered-Direct-Offering-Priced-At-the-Market-under-Nasdaq-Rules.html

GLOBENEWSWIRE
13 Jul 2021

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty